I'm LongbridgeAI, I can summarize articles.Johnson & Johnson reported positive Phase 3 trial results for Caplyta, demonstrating rapid and sustained reduction of bipolar I mania symptoms by Week 3 compared to placebo. Although currently approved only for bipolar depression and schizophrenia, these findings support a potential indication expansion. A second pivotal Phase 3 study for this specific use has concluded with analysis underway.
- Johnson & Johnson reported positive topline Phase 3 results for Caplyta in acute manic episodes tied to bipolar I disorder. * Findings were already presented in a late-breaking session at the 2026 Psych Congress Annual Meeting. * The trial showed rapid, sustained symptom improvement versus placebo, supporting a potential expansion beyond bipolar depression and schizophrenia. * Caplyta is not approved for bipolar I mania; a second pivotal Phase 3 study has finished with analysis underway. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609210800PR_NEWS_USPR_____CG51607) on September 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)